enamine fda approved drugs collection  (TargetMol)

Journal: iScience

Article Title: A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models

doi: 10.1016/j.isci.2026.115839

Figure Lengend Snippet: High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) Prestwick FDA (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.

Article Snippet: Prestwick FDA approved Drug Library , Prestwick Chemical , https://www.prestwickchemical.com/screening-libraries/prestwick-chemical-library/.

Techniques: Drug discovery, High Content Screening, Plasmid Preparation, Labeling

Journal: Signal Transduction and Targeted Therapy

Article Title: Glucocorticoids elevate clear cell renal cell carcinoma sensitivity to HIF-2α inhibitors by suppressing H4K12 lactylation

doi: 10.1038/s41392-026-02622-7

Figure Lengend Snippet: Six GCs inhibited H4K12la in ccRCC cells. a Experimental workflow of high-content drug screening for the quantification of H4K12la in 786-O control cells. 786-O cells were seeded in 384-well plates and then treated with FDA-approved drugs ( n = 2468) for 48 h. 786-O cells treated with vehicle were used as controls. Immunofluorescence staining of 786-O cells with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). High-content analysis with automatic image processing was applied to determine the mean immunofluorescence intensity per cell. b The relative average fluorescence intensity (RAFI) of 786-O cells treated with FDA-approved drugs compared with the vehicle control group. The drugs that caused a significant decrease in the relative average immunofluorescence intensity of H4K12la compared with that of the control group are labeled in red. A 40% reduction in the RAFI was considered to indicate a remarkable decrease (RAFI < 0.6, n = 15). c The top 15 drugs in terms of average fluorescence intensity compared with the vehicle control group. Blue, control group; red, GCs. d Immunofluorescence staining of 786-O cells treated with vehicle or the indicated GCs (10 μM), including DEX, BEC, FLUD, FLUO, MOME, and PRED, for 48 h with H4K12la antibody (green). DAPI staining was used to visualize the nucleus (blue). Bar, 50 μm. e Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or the indicated drugs (10 μM) for 48 h. f Western blot analysis of H4K12la and H3K18la in 786-O cells treated with vehicle or DEX at the indicated concentrations for 48 h

Article Snippet: The agents used were belzutifan and SO (MedChemExpress, MCE), DEX, DCA, sodium lactate, and the FDA-approved drug library (Selleck).

Techniques: Drug discovery, Control, Immunofluorescence, Staining, High Content Screening, Fluorescence, Labeling, Western Blot